VANCOUVER, British Columbia, Jan. 15, 2026 (GLOBE NEWSWIRE) -- Hydreight Technologies Inc. (TSXV:NURS, OTC:HYDTF, FSE: SO6)) ("Hydreight" or the "Company"), a leader in U.S. nationwide digital healthcare solutions, announced that it has entered into an agreement with Canaccord Genuity Corp. (the "Lead Underwriter") as lead underwriter and sole bookrunner, and a syndicate of underwriters to be formed (collectively with the Lead Underwriter, the "Underwriters") pursuant to which the Company has launched a "bought deal" private placement of 2,470,000 units of the Company (each, a "Unit") at a price of C$4.05 per Unit (the "Issue Price") for aggregate gross proceeds of C$10,003,500 (the "Underwritten Offering").
Shane Madden, the CEO of the Company, comments: "Q4 demonstrated the continued and accelerating strength of our model, expanding proven pharmacy product lines and launching high-demand products drives real, scalable growth. This financing will allow us to further accelerate that momentum and expedite customer growth on all three verticals by expanding our technology and platform offerings, expanding production capacity, accelerating new product rollouts, and strengthening the infrastructure needed to support growing demand across our nationwide platform."
Each Unit will consist of one common share of the Company (a "Common Share"), and one half of one common share purchase warrant of the Company (each whole warrant, a "Warrant"). Each Warrant will entitle the holder thereof to purchase one Common Share at a price of C$5.27 at any time on or before the date which is 24 months after the closing date of the Offering (the "Closing Date").
The Company will grant to the Underwriters an option, exercisable up to 48 hours prior to the Closing Date, to purchase for resale up to an additional 50% of the Units issued under the Underwritten Offering (the "Additional Units") at the Issue Price for additional gross proceeds of up to C$5,001,750 (the "Underwriters' Option" and, together with the Underwritten Offering, the "Offering"). The Units being offered pursuant to the Underwritten Offering, including the Additional Units that may be issued on exercise of the Underwriters' Option, shall be collectively referred to hereinafter as the "Offered Securities".
The net proceeds of the sale of the Offered Securities will be used to support sales growth, create new and expand existing pharmacy production lines, and for working capital and general corporate purposes, as more specifically described in the Offering Document.
The Offering will be completed on a private placement basis (i) in reliance on the "listed issuer financing" exemption from the prospectus requirements available under Part 5A.2 of National Instrument 45-106, ...
